Physician profile
Jorge F Robles
NPI 1366517716
$59,314.24
in general payments reported to CMS, 2019-2025
63 companies · $5,406 in 2025
The $5,406 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $4,769 · 2021: $6,670 · 2022: $2,390 · 2023: $2,339 · 2024: $5,235 · 2025: $5,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,874 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,100 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,873.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,100.00 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15,862.95 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $10,256.54 | 2019-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $6,788.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $5,010.15 | 2019-2023 | |
| Abbvie INC. | $4,596.25 | 2019-2025 | Vraylar, Linzess |
| Boston Scientific Corporation | $3,099.71 | 2019-2025 | Watchman Flx, Farapulse, Versacross Access Solution |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,643.51 | 2019-2025 | Jardiance |
| Genentech, INC. | $1,360.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,154.39 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,104.94 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Radius Health, INC. | $831.40 | 2020-2025 | Tymlos |
| Corcept Therapeutics | $773.21 | 2020-2025 | Korlym |
| Glaxosmithkline, LLC. | $624.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $573.47 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $568.38 | 2019-2024 | Evenity, Prolia, Tezspire |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.